請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77348
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 盧子彬(Tzu-Pin Lu) | |
dc.contributor.author | Han-Ching Chan | en |
dc.contributor.author | 詹涵晴 | zh_TW |
dc.date.accessioned | 2021-07-10T21:57:33Z | - |
dc.date.available | 2021-07-10T21:57:33Z | - |
dc.date.copyright | 2019-08-28 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-07-25 | |
dc.identifier.citation | 1. Taiwan Cancer Registry Annual Report of 2016. In.: National Health Promotion Administration Ministry of Health and Welfare; 2018.
2. Report of colorectal cancer prevention [https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=615&pid=1126] 3. Do Frequent Follow-Up Tests Benefit Colorectal Cancer Survivors? [https://www.cancer.gov/news-events/cancer-currents-blog/2018/colorectal-cancer-follow-up-testing] 4. Lin G-P, Lee K-D, Wang J-Y, Chen J-S, Chiang C-J, Yeh C-Y: Status for clinically complete remission rectal cancer after concomitant chemo-radiotherapy in Taiwan. Asian Journal of Surgery 2018, 41(3):203-209. 5. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer: International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. The Lancet 1995, 345(8955):939-944. 6. Group QC: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. The Lancet 2007, 370(9604):2020-2029. 7. Marshall JL, Haller DG, de Gramont A, Hochster HS, Lenz H-J, Ajani JA, Goldberg RM: Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology. Gastrointestinal cancer research : GCR 2007, 1(4):146-154. 8. Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thödtmann R, Tschmelitsch J, Jagoditsch M, Steger GG, Jakesz R, Herbst F et al: A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. British Journal Of Cancer 2007, 97:1021. 9. Varghese A: Chemotherapy for Stage II Colon Cancer. Clinics in colon and rectal surgery 2015, 28(4):256-261. 10. Burki TK: Overtreatment of younger patients with colon cancer. The Lancet Oncology 2015, 16(5):e203. 11. Summary of healthcare expense for top 10 cancer in Taiwan In.: National Health Promotion Administration Ministry of Health and Welfare; 2016. 12. III ABB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Cutsem EV et al: American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer. 2004, 22(16):3408-3419. 13. Eheman CR, O'Neil ME, Styles TS, Thompson TD, Morris CR, Babcock FA, Chen VW: Use of Adjuvant Chemotherapy among Stage II Colon Cancer Patients in 10 Population-Based National Program of Cancer Registries. Journal of registry management 2016, 43(4):179-186. 14. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530. 15. Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G, Mauriac L, Katsaros D, Molina F, Theillet C et al: A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2008, 14(6):1744-1752. 16. Navab R, Strumpf D, Bandarchi B, Zhu C-Q, Pintilie M, Ramnarine VR, Ibrahimov E, Radulovich N, Leung L, Barczyk M et al: Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proceedings of the National Academy of Sciences 2011, 108(17):7160. 17. Sanchez-Palencia A, Gomez-Morales M, Gomez-Capilla JA, Pedraza V, Boyero L, Rosell R, Fárez-Vidal ME: Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer. 2011, 129(2):355-364. 18. Larkin SET, Holmes S, Cree IA, Walker T, Basketter V, Bickers B, Harris S, Garbis SD, Townsend PA, Aukim-Hastie C: Identification of markers of prostate cancer progression using candidate gene expression. British Journal Of Cancer 2011, 106:157. 19. Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC et al: A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. European Urology 2014, 66(3):550-560. 20. Saintigny P, Zhang L, Fan Y-H, El-Naggar AK, Papadimitrakopoulou VA, Feng L, Lee JJ, Kim ES, Ki Hong W, Mao L: Gene expression profiling predicts the development of oral cancer. Cancer prevention research (Philadelphia, Pa) 2011, 4(2):218-229. 21. Wang Y, Klijn JGM, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J et al: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. The Lancet 2005, 365(9460):671-679. 22. Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, Lopez-Doriga A, Santos C, Marijnen C, Westerga J et al: Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer. 2011, 29(1):17-24. 23. Bolstad BM, Gautier L, Cope L, Irizarry RA: affy—analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004, 20(3):307-315. 24. preprocessCore: A collection of pre-processing functions. R package version 1.44.0. [https://github.com/bmbolstad/preprocessCore] 25. Chawla NV, Bowyer KW, Hall LO, Kegelmeyer WP: SMOTE: Synthetic Minority Over-sampling Technique. Journal of Artificial Intelligence Research 2002, 16:321-357. 26. Torgo L, Torgo M: Package ‘DMwR’. Comprehensive R Archive Network. In.; 2013. 27. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(9):5116-5121. 28. Tibshirani R, Chu G, Narasimhan B, Li J: samr: Significance analysis of microarrays. R package version 2011, 2. 29. Díaz-Uriarte R, Alvarez de Andrés S: Gene selection and classification of microarray data using random forest. BMC Bioinformatics 2006, 7(1):3. 30. Breiman L: Random Forests. Machine Learning 2001, 45(1):5-32. 31. Diaz-Uriarte R, Diaz-Uriarte MR: Package ‘varSelRF’. In.; 2017. 32. Cortes C, Vapnik VJML: Support-vector networks. 1995, 20(3):273-297. 33. Dimitriadou E, Hornik K, Leisch F, Meyer D, Weingessel A, Leisch MF: Package ‘e1071’. R Software package, avaliable at http://cran rproject org/web/packages/e1071/index html 2009. 34. Polikar R: Ensemble based systems in decision making. IEEE Circuits and Systems Magazine 2006, 6(3):21-45. 35. Breiman LJML: Bagging predictors. 1996, 24(2):123-140. 36. Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC, Lempicki RAJGB: The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. 2007, 8(9):R183. 37. Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F et al: A pathology atlas of the human cancer transcriptome. Science 2017, 357(6352):eaan2507. 38. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D et al: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603. 39. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SGF, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK et al: High-Resolution Crystal Structure of an Engineered Human 2-Adrenergic G Protein-Coupled Receptor. Science 2007, 318(5854):1258-1265. 40. Hasenoehrl C, Feuersinger D, Sturm EM, Bärnthaler T, Heitzer E, Graf R, Grill M, Pichler M, Beck S, Butcher L et al: G protein-coupled receptor GPR55 promotes colorectal cancer and has opposing effects to cannabinoid receptor 1. 2018, 142(1):121-132. 41. Gemignani F, Landi S, Moreno V, Gioia-Patricola L, Chabrier A, Guino E, Navarro M, Cambray M, Capellà G, Canzian F: Polymorphisms of the Dopamine Receptor Gene and Colorectal Cancer Risk. Cancer Epidemiology Biomarkers & Prevention 2005, 14(7):1633. 42. Lei Y, Huang K, Gao C, Lau QC, Pan H, Xie K, Li J, Liu R, Zhang T, Xie N et al: Proteomics identification of ITGB3 as a key regulator in reactive oxygen species-induced migration and invasion of colorectal cancer cells. Molecular & cellular proteomics : MCP 2011, 10(10):M110.005397-M005110.005397. 43. Slattery ML, Lundgreen A, Herrick JS, Kadlubar S, Caan BJ, Potter JD, Wolff RK: Variation in the CYP19A1 gene and risk of colon and rectal cancer. Cancer causes & control : CCC 2011, 22(7):955-963. 44. Bohanes P, Yang D, Loupakis F, LaBonte MJ, Gerger A, Ning Y, Lenz C, Lenz F, Wakatsuki T, Zhang W et al: Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer. The Pharmacogenomics Journal 2014, 15:226. 45. Ye P, Li Z, Jiang H, Liu TJCB, Biophysics: SNPs in MicroRNA-Binding Sites in the ITGB1 and ITGB3 3′-UTR Increase Colorectal Cancer Risk. 2014, 70(1):601-607. 46. Kline CLB, Ralff MD, Lulla AR, Wagner JM, Abbosh PH, Dicker DT, Allen JE, El-Deiry WS: Role of Dopamine Receptors in the Anticancer Activity of ONC201. Neoplasia (New York, NY) 2017, 20(1):80-91. 47. Asadi M, Shanehbandi D, Asvadi Kermani T, Sanaat Z, Zafari V, Hashemzadeh S: Expression Level of Caspase Genes in Colorectal Cancer. Asian Pac J Cancer Prev 2018, 19(5):1277-1280. 48. Dyrskjøt L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, Kotwal S, Knowles M, Malmström P-U, de la Torre M et al: Gene Expression Signatures Predict Outcome in Non–Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study. Clinical Cancer Research 2007, 13(12):3545. 49. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ et al: Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology. 2012, 367(8):705-715. 50. McIver B, Morris JC, Kosok L, Castro MR, Smallridge R, Bernet V, Henry M, Reddi H: An Independent Study of a Gene Expression Classifier (Afirma) in the Evaluation of Cytologically Indeterminate Thyroid Nodules. The Journal of Clinical Endocrinology & Metabolism 2014, 99(11):4069-4077. 51. Zemmour C, Bertucci F, Finetti P, Chetrit B, Birnbaum D, Filleron T, Boher J-M: Prediction of early breast cancer metastasis from DNA microarray data using high-dimensional cox regression models. Cancer informatics 2015, 14(Suppl 2):129-138. 52. Huang T-T, Pennarun N, Cheng Y-H, Horng C-F, Lei J, Hung-Chun Cheng S: Gene expression profiling in prognosis of distant recurrence in HR-positive and HER2-negative breast cancer patients. Oncotarget 2018, 9(33):23173-23182. 53. Cancer Research UK [https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer#heading-Four] 54. National Institute for Health and Care Excellence [https://www.nice.org.uk/] 55. Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi M-C, Schiappa R, Guenot D, Ayadi M et al: Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value. PLOS Medicine 2013, 10(5):e1001453. 56. Freeman TJ, Smith JJ, Chen X, Washington MK, Roland JT, Means AL, Eschrich SA, Yeatman TJ, Deane NG, Beauchamp RD: Smad4-Mediated Signaling Inhibits Intestinal Neoplasia by Inhibiting Expression of β-Catenin. Gastroenterology 2012, 142(3):562-571.e562. 57. Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J, Kerr D, Aaltonen LA, Arango D, Kruhøffer M et al: Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2009, 15(24):7642-7651. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77348 | - |
dc.description.abstract | 背景: 大腸直腸癌不論在台灣乃至全球都是發生率極高的一項癌症,隨著篩檢率的提高,也越發容易發現早期病人,而目前臨床上對於大腸直腸癌早期病人術後是否需進一步接受輔助性治療尚未有定論,針對何謂高風險復發病人的定義也尚未明確。本研究旨在藉由基因表現量資料找出在早期病人中有無復發組別間的差異表現基因,進一步建立模型來預測病人的復發風險,找出高復發風險的病人以進行進一步的治療。
方法: 本研究皆使用來自Gene Expression Omnibus (GEO)公開資料庫之基因表現量資料,其中由於訓練集資料GSE40967為不平衡資料,為了避免預測模型傾向判斷為多數類別,我們使用Synthetic Minority Over-sampling Technique (SMOTE)方法調整類別比例,對於少數分類類別使用過取樣增加虛擬樣本,對於多數類別使用簡單隨機欠抽樣方式減少樣本以達到平衡資料。在挑選差異表現基因方面,我們分別依序使用Significance Analysis of Microarrays (SAM)、羅吉斯迴歸以及隨機森林遞迴特徵消除法,在設定固定閥值後一一進行篩選,最後以Support Vector Machine (SVM)建立預測模型,此外為了得到更穩定的預測,我們運用平行集成的概念,使用Bagging方式抽取10次特定比例的訓練資料,分別進行同樣的分析流程並建立起10個獨立的預測模型,最後以多數決投票方式決定最終預測。 結果:在10個模型中,平均每個模型最終擁有11個差異表現基因,將10個模型取聯集後共可得到51個差異表現基因,在預測表現方面,訓練集的敏感度與特異度為91.18%及83.3%;外部驗證方面,敏感度與特異度在美國與澳洲方面分別為80%及37.78%與91.67%及32.84%。同時此研究也做了方法比較,分別比較了羅吉斯迴歸前進法與Lasso迴歸法,其兩者在訓練集的預測表現表現不差,但在外部驗證上仍無法保有高敏感度的特性。 結論:在此研究中,我們成功使用基因表現量資料找出差異表現基因,並建立預測模型找出高復發風險大腸直腸癌早期病人,以輔佐判斷病人到底需不需進行輔助性治療,此外,針對此研究所得到的差異表現基因仍待進一步確認與大腸直腸癌的關係與機制,並期望未來在治療上能有所幫助。 | zh_TW |
dc.description.abstract | Background: It is still unclear whether a patient with early stages colorectal cancer shall receive adjuvant chemotherapy or not. For the safety, patients usually undergo the treatment but only some of them do get the benefits. However, some patients suffer from the side effects but have no benefits. To address this issue, this study used gene expression profiles to develop a gene signature in order to identify early stages high-risk colorectal cancer patients who have a high probability of recurrence.
Methods: All the datasets analyzed were retrieved from public domains, including GSE40967, GSE17536, and GSE14333 from the GEO. First, we applied Synthetic Minority Over-sampling Technique (SMOTE), which is a technique to generate synthetic samples for addressing the problem of imbalanced data due to rare recurrence events. Next, a sequential workflow composed of three statistical methods (SAM, logistic regression and RFE with random forest) was utilized to obtain differentially expressed genes. In addition, we repeated the above processes to develop 10 independent prediction models by bagging training datasets using SVM. Lastly, the final prediction of the workflow was determined by an ensemble classifier. Results: The 10 prediction models included 51 unique differentially expressed genes, which can successfully predict the risk of recurrence within 3-year in the training dataset with sensitivity and specificity as 91.18% and 83.33% respectively. For the validation datasets, the sensitivity and specificity of samples from USA were 80% and 37.78% respectively, while that of Australia were 91.67% and 32.84% respectively. Conclusion: We identified a gene signature which can successfully determine high-risk of recurrence in early stages colorectal cancer patients from public gene expression datasets. The prediction models would potentially function as a tool to decide whether adjuvant chemotherapy should be undergone after surgery or not for patients with early stage colorectal cancer. | en |
dc.description.provenance | Made available in DSpace on 2021-07-10T21:57:33Z (GMT). No. of bitstreams: 1 ntu-108-R06849032-1.pdf: 3530142 bytes, checksum: 0e7b330318ab0af0db32385bb0502ed7 (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 口試委員審定書 i
致謝 ii 中文摘要 iii Abstract v 第一章 導論 1 1.1 研究背景 1 1.2 研究動機 1 1.3 研究目的 3 第二章 材料與方法 3 2.1 樣本 3 2.1.1 資料來源 3 2.1.2 樣本篩選 4 2.2 分析方法 4 2.2.1 臨床變項分析 4 2.2.2 人工少數類過取樣法(Synthetic Minority Over-sampling Technique, SMOTE) 5 2.2.3 微陣列顯著分析(Significance Analysis of Microarrays, SAM) 6 2.2.4 隨機森林遞迴特徵消除法(Recursive Feature Elimination with Random Forest, RFE with RF) 6 2.2.5 支援向量機 (Support Vector Machine, SVM) 7 2.2.6 平行集成方法(Parallel ensemble method) 8 2.2.7 功能預測分析(Functional analysis) 9 2.3 有效藥物預測 9 2.3.1 資料來源 9 2.3.2 藥物有效性 10 第三章 結果 10 3.1 資料篩選 10 3.2 模型建立 11 3.2.1 參數設定 11 3.2.2 差異表現基因篩選結果 12 3.3 預測結果 12 3.3.1 術後三年內復發狀態預測 12 3.3.2 外部資料驗證結果: 美國及澳洲 13 3.4 功能性預測分析 13 3.5 藥物預測結果 14 第四章 討論與結論 14 4.1 主要發現 14 4.2 方法比較 15 4.2.1 不平衡資料處理方法 15 4.2.2 建立模型方法表現比較 16 4.3 公共衛生與臨床意義 17 參考文獻 19 附錄 34 | |
dc.language.iso | zh-TW | |
dc.title | 建構大腸直腸癌病患之基因預後模型 | zh_TW |
dc.title | Development of a new prognostic gene expression
signature for colorectal cancer | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 蕭朱杏,林菀俞,蕭自宏,王彥雯 | |
dc.subject.keyword | 基因表現量,預後因子,大腸直腸癌,機器學習, | zh_TW |
dc.subject.keyword | gene expression,prognostic signature,colon and colorectal cancer,machine learning, | en |
dc.relation.page | 36 | |
dc.identifier.doi | 10.6342/NTU201901430 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2019-07-25 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-R06849032-1.pdf 目前未授權公開取用 | 3.45 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。